Mode
Text Size
Log in / Sign up

Sympathovagal imbalance correlates with IBS symptom severity and shows subtype specificity

Sympathovagal imbalance correlates with IBS symptom severity and shows subtype specificity
Photo by Rob Hobson / Unsplash
Key Takeaway
Note that reduced vagal tone correlates with IBS symptom severity and subtype specificity.

This review addresses neural dynamics in patients with irritable bowel syndrome. The scope focuses on the relationship between autonomic function and clinical presentation. The authors synthesize findings indicating that reduced vagal tone with relative sympathetic hyperactivity correlates with symptom severity and shows subtype specificity. No specific intervention or comparator was evaluated as the source is a review rather than a trial. The primary outcome described is the association between sympathovagal imbalance and symptom patterns. Absolute numbers and p-values were not reported in the source material. The review does not provide data on adverse events or tolerability. The authors acknowledge methodological limitations in assessing neural dynamics. They also highlight insufficient integration of multi-system interactions as a constraint. Practice relevance was not reported by the authors. The evidence is observational in nature and does not establish causality. Clinicians should interpret these findings within the context of existing diagnostic frameworks.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
This review synthesizes current evidence on autonomic nervous system (ANS) dysfunction in irritable bowel syndrome (IBS). Patients with IBS often exhibit sympathovagal imbalance–reduced vagal tone with relative sympathetic hyperactivity–which correlates with symptom severity and shows subtype specificity. The ANS orchestrates bidirectional brain–gut communication via interactions with psychosocial factors, low-grade neuroinflammation, and the gut microbiota. Key mechanisms include vagal afferent signaling by microbial metabolites, sympathetic regulation of mucosal immunity, stress-induced disruption of autonomic homeostasis, and neuroplastic changes in intestinal and central pain pathways. Emerging evidence supports therapeutic targeting of autonomic circuits through vagus nerve stimulation, pharmacological modulation of serotonin and adrenergic receptors, and microbiome-based interventions. Current challenges include methodological limitations in assessing neural dynamics and insufficient integration of multi-system interactions. Future research should employ multi-omics approaches to elucidate pathway-specific mechanisms and develop precision medicine strategies for this heterogeneous disorder.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.